Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
General19 hours agoAccused of Antisemitism: Herald Sun, Israel lobby v Dandenong Clr Rhonda Garad
-
Noosa News19 hours agoMitch Power Quick Shear event gets men talking about mental health
-
General21 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
General14 hours agoAFL Round 18 live updates: Bulldogs vs Crows, Giants vs Cats, Tigers vs Bombers, Dockers vs Hawks — blog, scores and stats